Compare Summit Therapeutics Inc (SMMT) vs Tencent Music Entertainment Group - ADR (TME) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs Tencent Music Entertainment Group - ADR — how do they compare? Summit Therapeutics Inc trades at $17.52 (market cap $13.79B), while Tencent Music Entertainment Group - ADR trades at $7.96 (market cap $13.50B). The key difference: Summit Therapeutics Inc and Tencent Music Entertainment Group - ADR are close in size by market cap, and Tencent Music Entertainment Group - ADR pays a 2.98% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| SMMT | TME | |
|---|---|---|
Market Cap | $13.79B | $13.50B |
Sector | Health | Media |
52-Week High | $26.38 | $26.36 |
52-Week Low | $12.43 | $7.89 |
Enterprise Value | $13.11B | $11.44B |
Dividend Yield | — | 2.98% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $17.28, down 1.85% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of $1.08 billion for 2025, negative ROE of -192.5%, and relies on financing cash flow for liquidity. Recent news highlights positive Phase III trial results for ivonescimab in lung and biliary tract cancers, driving investor optimism ahead of a key FDA decision in November 2026.
The outlook hinges on regulatory approval and commercial success of ivonescimab, with a consensus price target of $25.23 implying 46% upside. Risks include high cash burn, clinical trial uncertainties, and potential dilution from financing activities. Analyst sentiment is bullish (60.9% buy ratings), but the stock remains speculative due to its pre-revenue status and dependence on pipeline milestones.
Tencent Music Entertainment (TME) trades at $8.06, down 2.42% on the day, with technical indicators signaling a bearish trend. The company reported strong Q2 2026 earnings with an EPS beat of $0.25 versus $0.24 expected, and revenue growth to $32.9B in 2025. However, recent news highlights a $1 billion notes offering and mixed analyst sentiment amid competitive pressures.
TME presents a value opportunity with a low P/E of 9.46 and a consensus price target of $12.15, but faces risks from slowing growth and intense competition. Investors should weigh solid fundamentals against near-term headwinds in the music streaming sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About Tencent Music Entertainment Group - ADR
TME is the largest online music service provider in China. It was founded in 2016 with the business combination of QQ Music (founded in 2005), Kuwo Music (founded in 2005) and Kugou Music (founded in 2004) streaming platforms. Tencent is the largest shareholder of TME with over 50% shares and over 90% voting rights held. TME also provides social entertainment services, including music live audio/video broadcasts and online concert services through the three platforms mentioned above, and online karaoke through an independent platform WeSing.
Read more on TME →
